CA2345532A1 - Administration de polyphosphates phosphoinositides dans les cellules - Google Patents

Administration de polyphosphates phosphoinositides dans les cellules Download PDF

Info

Publication number
CA2345532A1
CA2345532A1 CA002345532A CA2345532A CA2345532A1 CA 2345532 A1 CA2345532 A1 CA 2345532A1 CA 002345532 A CA002345532 A CA 002345532A CA 2345532 A CA2345532 A CA 2345532A CA 2345532 A1 CA2345532 A1 CA 2345532A1
Authority
CA
Canada
Prior art keywords
cell
cells
group
label
nbd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002345532A
Other languages
English (en)
Inventor
Joseph Shope
Shoichiro Ozaki
Daryll B. Dewald
Glenn D. Prestwich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation UURF
Utah State University USU
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2345532A1 publication Critical patent/CA2345532A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)

Abstract

Cette invention vise à faciliter l'administration d'un polyphosphate de phosphatidylinositol ou d'un dérivé de ce composé dans une cellule eucaryote. Le procédé consiste à former un complexe de polyphosphate de phosphatidylinositol ou d'un dérivé de ce composé avec une polyamine, puis à mettre la cellule en contact avec ce complexe. Comme polyamines, on utilise de préférence des aminoglycosides, des polyamines dendrimériques, et des histones. L'invention concerne également des compositions pouvant être utilisées avec ce procédé. Elle porte également sur la recherche systématique de composés qui présentent une toxicité minimum pour les cellules eucaryotes et une toxicité maximum pour les cellules de bactérie. De plus, l'invention concerne la surveillance du flux de calcium dans une cellule.
CA002345532A 1998-09-30 1999-09-29 Administration de polyphosphates phosphoinositides dans les cellules Abandoned CA2345532A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10248298P 1998-09-30 1998-09-30
US60/102,482 1998-09-30
US39629699A 1999-09-15 1999-09-15
US09/396,296 1999-09-15
PCT/US1999/022594 WO2000018949A2 (fr) 1998-09-30 1999-09-29 Administration de polyphosphates phosphoinositides dans les cellules

Publications (1)

Publication Number Publication Date
CA2345532A1 true CA2345532A1 (fr) 2000-04-06

Family

ID=26799415

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002345532A Abandoned CA2345532A1 (fr) 1998-09-30 1999-09-29 Administration de polyphosphates phosphoinositides dans les cellules

Country Status (4)

Country Link
EP (1) EP1119315A4 (fr)
AU (1) AU6502699A (fr)
CA (1) CA2345532A1 (fr)
WO (1) WO2000018949A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265231B2 (en) 2000-05-31 2006-07-06 Promega Corporation Assay for kinases and phosphatases
CN1539021A (zh) 2001-06-11 2004-10-20 Ӧ���о�ϵͳARS�ɷݹ�˾ 氨基糖苷结合分子的新型亲近闪烁检测法
US20050118624A1 (en) * 2003-10-03 2005-06-02 Cumbre Inc. Fluorescent probes for ribosomes and method of use
WO2005063260A2 (fr) * 2003-12-22 2005-07-14 Oregon Health And Science University Procedes et composition pour prevenir des effets secondaires toxiques des medicaments a aminoglycosides
WO2005071095A2 (fr) 2004-01-16 2005-08-04 Applera Corporation Essais fluorogeniques pour kinase et substrats
US7659088B2 (en) * 2006-05-22 2010-02-09 Aureogen Biosciences, Inc. Assay for inositol phosphorylceramide synthase activity
GB0920985D0 (en) * 2009-11-30 2010-01-13 Queen Mary & Westfield College Novel inositol phosphate derivatives
US10350235B2 (en) 2015-08-19 2019-07-16 Joseph Kost Cationic polysaccharides for delivery of phosphoinositides to cells for therapeutic purpose

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1237670A (fr) * 1983-05-26 1988-06-07 Andrew S. Janoff Reduction de la toxicite de certains medicaments

Also Published As

Publication number Publication date
AU6502699A (en) 2000-04-17
WO2000018949A9 (fr) 2000-08-31
WO2000018949A2 (fr) 2000-04-06
EP1119315A2 (fr) 2001-08-01
WO2000018949A3 (fr) 2000-07-20
EP1119315A4 (fr) 2002-04-17

Similar Documents

Publication Publication Date Title
Komine et al. Vacuolar granules in Chlamydomonas reinhardtii: polyphosphate and a 70-kDa polypeptide as major components
Traynor-Kaplan et al. Transient increase in phosphatidylinositol 3, 4-bisphosphate and phosphatidylinositol trisphosphate during activation of human neutrophils
Brownstein et al. Coexistence of Several Putative Neurotransmitters in Single Identified Neurosn of Aplysia
Siderius et al. CHLAMYDOMONAS EUGAMETOS (CHLOROPHYTA) STORES PHOSPHATE IN POLYPHOSPHATE BODIES TOGETHER WITH CALCIUM 1
CA2345532A1 (fr) Administration de polyphosphates phosphoinositides dans les cellules
Nishizuka Three multifunctional protein kinase systems in transmembrane control
Pap et al. Peptide-based targeting of fluorophores to organelles in living cells
Fernandes-Cunha et al. Delivery of inorganic polyphosphate into cells using amphipathic oligocarbonate transporters
Daniels et al. Neuropeptide Y mobilizes intracellular Ca2+ and increases inositol phosphate production in human erythroleukemia cells
JP2003503423A (ja) キャリア内の生体分子相互作用の取込みおよび適用
Blázquez-Moraleja et al. Shedding light on the mitochondrial matrix through a functional membrane transporter
Smith et al. Studies on the localization of the cardiac glycoside receptor
US6090784A (en) RNA polymerase II peptides and methods of use
Gupta et al. Activation of heart sarcoplasmic reticulum Ca++-stimulated adenosine triphosphatase by insulin.
Buckler et al. Synthesis of [32P] phosphoramidate for use as a low molecular weight phosphodonor reagent
US11723985B2 (en) Protein delivery to membranes
US4571332A (en) 125 I and 131 I labeled phospholipids
EP0791056B1 (fr) Complexe d'enzyme de clivage de lipides
Cocco et al. Nuclear inositol lipid cycle and differentiation
EP4200609B1 (fr) Dosage pour mesurer l'affinité de liaison pour la cardiolipine de composés biologiquement actifs
DeWald et al. Cellular calcium mobilization in response to phosphoinositide delivery
Wirtz Peptide-based target-ing of fluorophores to organelles in living cells.
Huennekens et al. Membrane transport of folate compounds
Kawada et al. Inostamycin, an Inhibitor of P‐Glycoprotein Function, Interacts Specifically with Phosphatidylethanolamine
Raju et al. Identification of Biomolecules Involved in the Biosynthesis of Gold Nanoparticles from Living Peanut Seedlings

Legal Events

Date Code Title Description
FZDE Dead